Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T23090 |
CK2-IN-1
|
Others | Others |
CK2 inhibitor | |||
T10827 |
CK2/ERK8-IN-1
TMCB |
Apoptosis; ERK; Casein Kinase; Pim; DYRK | Apoptosis; Cell Cycle/Checkpoint; Chromatin/Epigenetic; JAK/STAT signaling; MAPK; Metabolism; Stem Cells; Tyrosine Kinase/Adaptors |
CK2/ERK8-IN-1 (TMCB) 是一种酪蛋白激酶 2 (CK2) (Ki 为 0.25 µM) 和 ERK8 (MAPK15, ERK7) 的双重抑制剂,IC50 均为 0.50 μM。CK2/ERK8-IN-1 也与 PIM1,HIPK2 和 DYRK1A 结合,Ki 值分别为 8.65 µM,15.25 µM 和 11.9 µM。 | |||
T10828 |
CK2/PIM1-IN-1
|
Others | Others |
CK2/PIM1-IN-1 is an inhibitor of CK2 and PIM1 (IC50s: 3.787 μM and 4.327 μM). It is developed for the research of proliferative disorders such as cancer, as well as other kinase-associated conditions. | |||
T63991 | BRD4/CK2-IN-1 | ||
BRD4/CK2-IN-1 是高效的、口服具有活力的 BRD4/CK2 (含溴结构域蛋白 4/酪蛋白激酶 2) 双靶点抑制剂,能够作用于 BRD4 (IC50: 180 nM) 和 CK2 (IC50: 230 nM)。在三阴性乳腺癌 (TNBC) 中,BRD4/CK2-IN-1 能够诱导细胞凋亡和自噬相关的细胞死亡。BRD4/CK2-IN-1 表现出显著的抗癌效果,且没有明显毒性。 | |||
T35557 |
CK2 inhibitor 2
|
Casein Kinase | Metabolism; Stem Cells |
CK2 inhibitor 2 是一种有效的,选择性和口服CK2抑制剂,IC50值为 0.66 nM。CK2 inhibitor 2 对 Clk2 (IC50=32.69 nM)/CK2 显示出高选择性。 CK2 inhibitor 2 表现出良好的抗增殖和抗肿瘤活性。 | |||
T40131 |
SGC-CK2-1
SGC-CK2-1 |
||
SGC-CK2-1 is an ATP-competitive chemical compound that acts as a highly potent and cell-active CK2 inhibitor. It demonstrates excellent selectivity towards both isoforms of human CK2, with IC50 values of 36 nM for CK2α and 16 nM for CK2α′ in the nanoBRET assay. Given its properties, SGC-CK2-1 is a suitable tool for the investigation of neurodegenerative diseases. | |||
T78599 | CK2-IN-9 | ||
CK2-IN-9是一种有效的CK2 kinase选择性抑制剂,IC50值为3 nM。它能降低Wnt报告因子的活性,达到IC50为75 nM。在大鼠体内显示出低暴露量(AUC=0.36 μM/h)及高清除率(CL=65 mL/min/kg)。 | |||
T83684 |
Myelin Basic Protein Peptide (mouse, bovine) TFA
Gln-Lys-Arg-Pro-Ser-Gln-Arg-Ser-Lys-Tyr-Leu,MBP Peptide |
||
Myelin基础蛋白(MBP)肽是PKC的肽底物,相比PKA、酪蛋白激酶1(CK1)、CK2、磷酸化酶激酶及钙/钙调蛋白依赖性蛋白激酶(CaMKII),它对PKC有选择性。MBP肽已用于监测原发性人类肾动脉平滑肌细胞中的PKC活性。 |